# Chimera Project Governance

<div align="center">

![Chimera Governance](https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20GOVERNANCE%20%F0%9F%A6%BE-6236FF?style=for-the-badge&labelColor=1A1A2E)

**Comprehensive Governance Framework for the Chimera Brain-Controlled Exoskeleton Platform**

[![Project Status](https://img.shields.io/badge/Status-Active-brightgreen?style=flat-square)](https://github.com/chimera-org/chimera_v2.0)
[![License](https://img.shields.io/github/license/heya-vyom/chimera_v2.0?style=flat-square&logo=apache&logoColor=white)](LICENSE)
[![FDA Compliance](https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+)](regulatory/fda_strategy.md)
[![CDSCO](https://img.shields.io/badge/CDSCO-MDR%202017-orange?style=flat-square)](https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/)
[![Make in India](https://img.shields.io/badge/Make%20in%20India-Initiative-orange?style=flat-square)](https://www.makeinindia.com/)
[![ISO 13485](https://img.shields.io/badge/ISO%2013485-Compliant-blue?style=flat-square)](https://www.iso.org/standard/59752.html)
[![Home Use](https://img.shields.io/badge/Home%20Use-Certified-blue?style=flat-square)](https://www.iso.org/standard/60601-1-11.html)

</div>

## üìã Document Information

| **Document Information** |                                                |
|--------------------------|------------------------------------------------|
| **Document ID**          | GOV-FRAMEWORK-002                              |
| **Version**              | 2.0.0                                          |
| **Date Created**         | April 18, 2025                                 |
| **Last Updated**         | April 20, 2025                                 |
| **Author**               | Chimera Governance Team                        |
| **Reviewers**            | CEO, CTO, Clinical Director, Quality Director, Regulatory Affairs Director |
| **Status**               | Approved                                       |

## üìù Document Revision History

| Version | Date | Author | Description of Changes |
|---------|------|--------|------------------------|
| 1.0.0 | April 18, 2025 | Governance Team | Initial version |
| 2.0.0 | April 20, 2025 | Governance Team | Enhanced with comprehensive quality management system details, expanded regulatory compliance for Indian market, added home use governance, funding readiness sections, and detailed implementation plans |

## üéØ Purpose and Scope

### 1.1 Purpose

This Governance document establishes the comprehensive framework for decision-making, project management, quality control, regulatory compliance, and stakeholder participation within the Chimera project. It defines the organizational structure, roles and responsibilities, and processes that govern the development, maintenance, and evolution of the Chimera brain-controlled exoskeleton platform, with specific focus on its application as a home use medical device in the Indian market.

### 1.2 Scope

This Governance framework applies to:

- All components of the Chimera neural interface system and exoskeleton platform
- All contributors, maintainers, stakeholders, and investors involved in the project
- All development, testing, regulatory, clinical, and commercial activities
- All decision-making processes related to the project's technical direction, strategic goals, and funding initiatives
- All geographical markets, with specific focus on Indian regulatory requirements and home use applications
- All aspects of quality management and regulatory compliance necessary for billion-dollar funding readiness
- All processes related to unsupervised home use of the device after patient training

## üåê Principles

The Chimera project adheres to the following principles:

- **Open and Transparent**: Development, decision-making, and communication are conducted openly and transparently.
- **Inclusive and Respectful**: We welcome contributions from everyone and treat all participants with respect, as outlined in our [Code of Conduct](CODE_OF_CONDUCT.md).
- **Quality-Focused**: We prioritize quality, safety, and regulatory compliance in all aspects of the project, adhering to ISO 13485 standards.
- **Merit-Based**: Decisions and contributions are evaluated based on their technical merit and alignment with project objectives.
- **Regulatory Compliant**: We adhere to relevant regulatory frameworks, particularly Indian CDSCO requirements under Medical Devices Rules, 2017.
- **Patient-Centered**: The needs, safety, and autonomy of patients using our technology in home environments are at the center of all decisions.
- **Culturally Sensitive**: We recognize and respect the cultural diversity of the Indian market in our design and implementation.
- **Economically Viable**: We balance innovation with cost-effectiveness to ensure accessibility in the Indian healthcare context.
- **Funding Ready**: We maintain documentation and processes at standards expected by billion-dollar investors.

## üë• Project Structure

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1ksFugzAMhl_F8qkV6hvkgNqqE5PW7TDtsFxCcWA0JVHiVFOFePfFQKHVNF8S-_-_2I4PrFCJkMEbsZqUxg_JrUZSLIpPSN5ajeSgHUkR0BmtfUL6qkVAQchrFESKkApwQVp4QyrAWZiGaZiGafgXO99HFeAiTMM0TMM0TMO_2FmAyzAN0zAN0zANY-fnqAJchWmYhmmYhmmYhrHzW1QBrsM0TMM0TMM0TMPY-SOqADdhGqZhGqZhGqZh7PwZVYC7MA3TMA3TMA3TMHZ-jyrAQ5iGaZiGaZiGaRg7H6MK8BimYRqmYRqmYRrGzlNUAZ7CNEzDNEzDNEzD2DmPKsBTmIZpmIZpmIZpGDsXUQV4CtMwDdMwDdMwDWPnMqoAz2EapmEapmEapmHsXEUV4DlMwzRMwzRMwzSMneuoAryEaZiGaZiGaZiGsXMTVYCXMA3TMA3TMA3TMHZuowrwEqZhGqZhGqZhGsbOXVQBXsM0TMM0TMM0TMPYuY8qwGuYhmmYhmmYhmkYOw9RBXgN0zAN0zAN0zANY-cxqgCvYRqmYRqmYRqmYew8RRXgLUzDNEzDNEzDNIyd56gCvIVpmIZpmIZpmIaxcxFVgLcwDdMwDdMwDdMwdi6jCvAepmEapmEapmEaxs5VVAHewzRMwzRMwzRMw9i5jirAe5iGaZiGaZiGaRg7N1EFeA_TMA3TMA3TMA1j5zaqAB9hGqZhGqZhGqZh7NxFFeAjTMM0TMM0TMM0jJ37qAJ8hGmYhmmYhmmYhrHzEFWAjzAN0zAN0zAN0zB2HqMK8BGmYRqmYRqmYRrGzlNUAT7DNEzDNEzDNEzD2HmOKsBnmIZpmIZpmIZpGDsXUQX4DNMwDdMwDdMwDWPnMqoAX2EapmEapmEapmHsXEUV4CtMwzRMwzRMwzSMneuoAvwO0zAN0zAN0zANY-cmqgC_wzRMwzRMwzRMw9i5jSrA7zAN0zAN0zAN0zB27qIK8CdMwzRMwzRMwzSMnfuoAvwJ0zAN0zAN0zANY-chqgB_wjRMwzRMwzRMw9h5jCrAnzAN0zAN0zAN0zB2nqIK8DdMwzRMwzRMwzSMneeoAvwN0zAN0zAN0zANY-ciqgB_wzRMwzRMwzRMw9i5jCrAvzAN0zAN0zAN0zB2rqIK8C9MwzRMwzRMwzSMneuoAvwL0zAN0zAN0zANY-cmqgD_wjRMwzRMwzRMw9i5jSrA_zAN0zAN0zAN0zB27qIK8H-YhmmYhmmYhmkYO_dRBfgfpmEapmEapmEaxs5DVAH-h2mYhmmYhmmYhrHzGFWA_2EapmEapmEapmHsPEUV4CtMwzRMwzRMwzSMnef4D5aTJwA?type=png" alt="Chimera Project Structure" width="700px" />
</div>

### 3.1 Core Team

The Core Team is responsible for the overall direction, strategy, and governance of the Chimera project. It consists of:

- **Chief Executive Officer (CEO)**: Responsible for overall business strategy, funding, and external relationships.
- **Chief Technology Officer (CTO)**: Responsible for technical vision, architecture, and engineering leadership.
- **Clinical Director**: Responsible for clinical validation, patient safety, and medical oversight.
- **Quality Director**: Responsible for quality management system and regulatory compliance.
- **Regulatory Affairs Director**: Responsible for regulatory strategy and submissions.
- **Chief Financial Officer (CFO)**: Responsible for financial planning, investor relations, and funding strategy.
- **Chief Operating Officer (COO)**: Responsible for day-to-day operations, manufacturing, and supply chain.

The Core Team makes decisions by consensus, with the CEO having the final decision-making authority in case of deadlock.

### 3.2 Technical Steering Committee (TSC)

The Technical Steering Committee oversees the technical direction of the project. It consists of:

- **CTO (Chair)**
- **Lead Software Architect**
- **Lead ML Engineer**
- **Lead Hardware Engineer**
- **Lead Clinical Engineer**
- **Security Officer**
- **Quality Engineer**
- **Home Use Specialist**
- **Accessibility Expert**

The TSC is responsible for:

- Defining technical roadmap and priorities
- Approving major architectural decisions
- Reviewing and approving technical specifications
- Ensuring technical quality and consistency
- Resolving technical disputes
- Ensuring suitability for home use in Indian environments
- Addressing infrastructure challenges specific to the Indian market

The TSC meets weekly and makes decisions by consensus. If consensus cannot be reached, the CTO has the final decision-making authority.

### 3.3 Working Groups

Working Groups are formed to address specific areas of the project. Current Working Groups include:

#### 3.3.1 ML Pipeline Working Group
- Responsible for the development and maintenance of the ML pipeline
- Focuses on data processing, feature extraction, model training, and evaluation
- Led by the Lead ML Engineer
- Ensures algorithms function reliably in home environments with varied conditions
- Develops offline processing capabilities for areas with limited connectivity

#### 3.3.2 Hardware Integration Working Group
- Responsible for the integration of the software with the exoskeleton hardware
- Focuses on hardware interfaces, real-time control, and physical safety mechanisms
- Led by the Lead Hardware Engineer
- Ensures hardware resilience to power fluctuations common in India
- Develops solutions for operation in high humidity and dust environments

#### 3.3.3 Clinical Validation Working Group
- Responsible for the design and execution of clinical validation studies
- Focuses on protocol development, data collection, and analysis
- Led by the Clinical Director
- Ensures validation includes home use scenarios across diverse Indian settings
- Develops training protocols for patients and family members

#### 3.3.4 Regulatory Compliance Working Group
- Responsible for ensuring compliance with regulatory requirements
- Focuses on documentation, risk management, and submission preparation
- Led by the Regulatory Affairs Director
- Specializes in CDSCO requirements under Medical Devices Rules, 2017
- Ensures compliance with home use medical device regulations

#### 3.3.5 Security Working Group
- Responsible for ensuring the security of the system
- Focuses on threat modeling, security testing, and vulnerability management
- Led by the Security Officer
- Addresses security considerations for home networks and varied connectivity
- Implements robust authentication suitable for diverse literacy levels

#### 3.3.6 Home Use Adaptation Working Group
- Responsible for ensuring the system is suitable for home use without professional supervision
- Focuses on usability, safety features, and user training
- Led by the Home Use Specialist
- Develops solutions for Indian home environments and infrastructure challenges
- Creates culturally appropriate training materials in multiple Indian languages

#### 3.3.7 Quality Management Working Group
- Responsible for implementing and maintaining the quality management system
- Focuses on ISO 13485 compliance and quality processes
- Led by the Quality Director
- Ensures quality processes support billion-dollar funding requirements
- Develops quality metrics specific to home use applications

#### 3.3.8 Funding Readiness Working Group
- Responsible for ensuring the project meets investor expectations
- Focuses on documentation, business planning, and market analysis
- Led by the CFO
- Prepares materials for billion-dollar funding rounds
- Develops financial models and ROI projections

### 3.4 Advisory Boards

#### 3.4.1 Clinical Advisory Board
- Provides expert medical input on clinical applications and safety
- Consists of neurologists, rehabilitation specialists, and other medical experts
- Includes representation from major Indian medical institutions
- Advises on home use safety protocols and patient selection criteria
- Details defined in [Clinical Advisory Board Charter](clinical/advisory_board/india_advisory_board_charter_v1.0.md)

#### 3.4.2 Patient Advisory Board
- Provides perspective from potential users of the technology
- Consists of individuals with mobility impairments and their caregivers
- Ensures diverse representation across Indian demographics
- Advises on usability, accessibility, and real-world considerations
- Provides feedback on home use experience and training materials

#### 3.4.3 Regulatory Advisory Board
- Provides guidance on regulatory strategy and compliance
- Consists of regulatory experts with experience in Indian medical device regulations
- Advises on CDSCO submissions and compliance requirements
- Helps navigate the evolving regulatory landscape for novel medical technologies
- Provides insights on home use regulatory considerations

#### 3.4.4 Investor Advisory Board
- Provides guidance on funding strategy and investor relations
- Consists of experienced investors and financial advisors
- Advises on preparation for billion-dollar funding rounds
- Helps identify and address potential investor concerns
- Provides market insights and valuation guidance

### 3.5 Contributors

Contributors are individuals who contribute to the project in various ways, including:

- Code contributions
- Documentation
- Testing
- Bug reports
- Feature requests
- Design input
- Clinical expertise
- Regulatory knowledge
- Cultural and linguistic expertise

Contributors are expected to follow the [Contributing Guidelines](CONTRIBUTING.md) and adhere to the [Code of Conduct](CODE_OF_CONDUCT.md).

## üîÑ Decision-Making Process

### 4.1 Technical Decisions

Technical decisions follow a consensus-seeking process:

1. **Proposal**: Any contributor can propose a technical change by creating an issue or pull request.
2. **Discussion**: The proposal is discussed openly, with feedback from relevant stakeholders.
3. **Refinement**: The proposal is refined based on feedback.
4. **Decision**: The decision is made by consensus among the relevant Working Group or TSC.
5. **Implementation**: Once approved, the change is implemented and reviewed.

For significant architectural or design decisions, a formal RFC (Request for Comments) process is used:

1. Create an RFC document in the `rfcs/` directory
2. Submit it as a pull request
3. Gather feedback from the community and relevant stakeholders
4. Refine the RFC based on feedback
5. TSC reviews and approves or rejects the RFC
6. If approved, the RFC is merged and implementation can begin

### 4.2 Strategic Decisions

Strategic decisions about project direction, priorities, and resource allocation are made by the Core Team. The process includes:

1. **Input Gathering**: Collecting input from Working Groups, TSC, Advisory Boards, and external stakeholders
2. **Analysis**: Analyzing options and their implications
3. **Proposal**: Developing a proposal for discussion
4. **Review**: Reviewing the proposal with key stakeholders
5. **Decision**: Making a decision by consensus, with the CEO having final authority
6. **Communication**: Communicating the decision to all stakeholders

### 4.3 Regulatory Decisions

Regulatory decisions follow a structured process:

1. **Regulatory Analysis**: The Regulatory Compliance Working Group analyzes requirements and options.
2. **Risk Assessment**: The Quality Management Working Group conducts risk assessment.
3. **Recommendation**: A recommendation is developed based on analysis and assessment.
4. **Review**: The recommendation is reviewed by the Regulatory Advisory Board.
5. **Approval**: The Core Team approves the regulatory approach.
6. **Implementation**: The approved approach is implemented and documented.

### 4.4 Funding Decisions

Funding decisions follow a dedicated process:

1. **Opportunity Assessment**: The Funding Readiness Working Group assesses funding opportunities.
2. **Due Diligence Preparation**: Documentation and evidence are prepared for investor review.
3. **Valuation Analysis**: The CFO conducts valuation analysis with external advisors.
4. **Term Sheet Review**: Proposed investment terms are reviewed by legal counsel.
5. **Negotiation Strategy**: The Core Team develops negotiation strategy.
6. **Final Approval**: The CEO and Board of Directors approve final investment terms.

### 4.5 Conflict Resolution

When conflicts arise, they are resolved through the following process:

1. **Direct Discussion**: Parties involved attempt to resolve the conflict directly.
2. **Mediation**: If direct discussion fails, a neutral third party mediates.
3. **Working Group Review**: If mediation fails, the relevant Working Group reviews the conflict.
4. **TSC Review**: If the Working Group cannot resolve the conflict, the TSC reviews it.
5. **Core Team Decision**: If the TSC cannot resolve the conflict, the Core Team makes the final decision.
6. **External Arbitration**: For significant conflicts involving external stakeholders, formal arbitration may be used.

## üìä Project Management

### 5.1 Development Process

The Chimera project follows a structured development process:

1. **Planning**: Requirements gathering, feature prioritization, and sprint planning
2. **Design**: Architecture and detailed design, including formal review
3. **Implementation**: Coding, unit testing, and code review
4. **Testing**: Integration testing, system testing, and validation
5. **Release**: Version control, release notes, and deployment
6. **Maintenance**: Bug fixes, updates, and continuous improvement

The development process incorporates:

- **Design Controls**: Following ISO 13485 requirements for medical device development
- **Risk Management**: Continuous risk assessment and mitigation throughout development
- **Verification and Validation**: Comprehensive testing to ensure requirements are met
- **Traceability**: Maintaining traceability between requirements, design, implementation, and testing
- **Home Use Considerations**: Specific testing for unsupervised use scenarios
- **Indian Market Adaptation**: Testing under conditions representative of Indian environments

### 5.2 Issue Management

Issues are tracked in the GitHub issue tracker and categorized as:

- **Bug**: A defect in the existing functionality
- **Feature**: A new feature or enhancement
- **Documentation**: Improvements to documentation
- **Question**: Questions about usage or implementation
- **Task**: General tasks that don't fit other categories
- **Regulatory**: Issues related to regulatory compliance
- **Quality**: Issues related to quality management
- **Home Use**: Issues specific to home use applications
- **India-Specific**: Issues related to Indian market adaptation

Issues are prioritized as:

- **Critical**: Must be fixed immediately (e.g., safety issues, blocking issues)
- **High**: Should be fixed in the current development cycle
- **Medium**: Should be fixed in a future development cycle
- **Low**: Nice to have, but not critical

### 5.3 Release Management

The project follows a semantic versioning scheme (MAJOR.MINOR.PATCH):

- **MAJOR**: Incompatible API changes or significant new functionality
- **MINOR**: Backwards-compatible functionality additions
- **PATCH**: Backwards-compatible bug fixes

Release process:

1. **Feature Freeze**: No new features after this point, only bug fixes
2. **Release Candidate**: Testing and validation of the release candidate
3. **Regulatory Review**: Review by Regulatory Compliance Working Group
4. **Quality Assurance**: Comprehensive testing by Quality Management Working Group
5. **Final Release**: Official release with release notes
6. **Post-Release Monitoring**: Monitoring and addressing any issues

For regulated versions:

1. **Design History File Review**: Comprehensive review of all design documentation
2. **Risk Management File Review**: Review of risk management documentation
3. **Verification and Validation Summary**: Compilation of all V&V results
4. **Regulatory Submission Preparation**: Preparation of regulatory submission documents
5. **Release Approval**: Formal approval by Quality Director and Regulatory Affairs Director
6. **Change Control**: Implementation of change control procedures for post-release changes

### 5.4 Documentation Management

Documentation is maintained in the following categories:

- **User Documentation**: Instructions for end-users and family caregivers
- **Clinical Documentation**: Guidelines for healthcare professionals
- **Developer Documentation**: Information for developers contributing to the project
- **Regulatory Documentation**: Documentation required for regulatory submissions
- **Quality Documentation**: Documentation related to the quality management system
- **Business Documentation**: Documentation for investors and business partners

All documentation follows:

- **Document Control**: Formal procedures for creation, review, approval, and versioning
- **Accessibility**: Multiple language support and consideration for varied literacy levels
- **Cultural Sensitivity**: Adaptation for Indian cultural context
- **Regulatory Compliance**: Adherence to documentation requirements of relevant regulations
- **Investor Readiness**: Professional presentation suitable for billion-dollar funding due diligence

## üîí Quality and Compliance

### 6.1 Quality Management System

The Chimera project maintains a comprehensive Quality Management System (QMS) that complies with ISO 13485:2016 and relevant regulatory requirements. The QMS includes:

#### 6.1.1 Quality Manual
- Defines the overall quality policy and objectives
- Describes the structure of the quality management system
- Identifies processes and their interactions
- Defines roles and responsibilities for quality management

#### 6.1.2 Quality Processes
- **Document Control**: Procedures for creating, reviewing, approving, and versioning documents
- **Record Control**: Procedures for maintaining and retrieving quality records
- **Internal Audit**: Procedures for planning and conducting internal audits
- **Corrective and Preventive Action (CAPA)**: Procedures for addressing issues and preventing recurrence
- **Management Review**: Procedures for reviewing the effectiveness of the QMS
- **Training**: Procedures for ensuring personnel competence
- **Supplier Management**: Procedures for evaluating and monitoring suppliers

#### 6.1.3 Design and Development
- **Design Planning**: Procedures for planning design and development activities
- **Design Inputs**: Procedures for defining and documenting requirements
- **Design Outputs**: Procedures for documenting design specifications
- **Design Review**: Procedures for reviewing design at appropriate stages
- **Design Verification**: Procedures for ensuring design outputs meet inputs
- **Design Validation**: Procedures for ensuring the product meets user needs
- **Design Transfer**: Procedures for transferring design to production
- **Design Changes**: Procedures for controlling design changes

#### 6.1.4 Production and Process Controls
- **Production Planning**: Procedures for planning production activities
- **Process Validation**: Procedures for validating production processes
- **Product Identification and Traceability**: Procedures for identifying and tracking products
- **Inspection and Testing**: Procedures for verifying product conformity
- **Nonconforming Product**: Procedures for controlling nonconforming products
- **Monitoring and Measurement**: Procedures for monitoring processes and products

#### 6.1.5 Home Use Considerations
- **Usability Engineering**: Procedures for ensuring usability in home environments
- **Home Environment Testing**: Procedures for testing under home conditions
- **User Training Validation**: Procedures for validating user training effectiveness
- **Remote Monitoring**: Procedures for monitoring device performance remotely
- **Technical Support**: Procedures for providing technical support to home users

### 6.2 Regulatory Compliance

The project is designed to comply with relevant regulatory requirements, including:

#### 6.2.1 Indian Regulatory Framework
- **Medical Devices Rules, 2017**: Compliance with all applicable requirements
- **CDSCO Guidelines**: Adherence to Central Drugs Standard Control Organization guidelines
- **IS 23485:2023**: Compliance with Indian Standard for Medical Devices Quality Management Systems
- **Home Use Requirements**: Compliance with specific requirements for home use medical devices
- **Make in India Initiative**: Alignment with Make in India manufacturing requirements

#### 6.2.2 International Standards
- **ISO 13485:2016**: Medical devices ‚Äî Quality management systems
- **ISO 14971:2019**: Medical devices ‚Äî Application of risk management to medical devices
- **IEC 62304:2006+AMD1:2015**: Medical device software ‚Äî Software life cycle processes
- **IEC 62366-1:2015**: Medical devices ‚Äî Application of usability engineering to medical devices
- **IEC 60601-1:2005+AMD1:2012+AMD2:2020**: Medical electrical equipment ‚Äî General requirements
- **IEC 60601-1-11:2015**: Requirements for medical electrical equipment used in the home healthcare environment

#### 6.2.3 Regulatory Strategy
- **Classification**: Class C medical device under Medical Devices Rules, 2017
- **Conformity Assessment**: Following Schedule 5 requirements for Class C devices
- **Clinical Investigation**: Planning and execution of clinical investigations
- **Post-Market Surveillance**: Procedures for monitoring device performance after market introduction
- **Adverse Event Reporting**: Procedures for reporting adverse events to regulatory authorities

#### 6.2.4 Regulatory Documentation
- **Technical File**: Comprehensive documentation of device design, risk management, and testing
- **Clinical Evaluation Report**: Documentation of clinical evidence supporting device safety and performance
- **Declaration of Conformity**: Formal declaration of compliance with regulatory requirements
- **Registration Application**: Documentation for device registration with CDSCO
- **Import License Application**: Documentation for import license (if applicable)
- **Manufacturing License Application**: Documentation for manufacturing license

### 6.3 Risk Management

The project implements a comprehensive risk management process following ISO 14971:2019:

#### 6.3.1 Risk Management Plan
- Defines the scope of risk management activities
- Establishes criteria for risk acceptability
- Defines roles and responsibilities for risk management
- Specifies requirements for review of risk management activities
- Details in [Risk Management Plan](regulatory/risk_management/india_risk_management_plan_v2.0.md)

#### 6.3.2 Risk Analysis
- Identification of hazards associated with the device
- Estimation of risks for each hazardous situation
- Evaluation of risks against acceptability criteria
- Special focus on home use and Indian infrastructure hazards
- Details in [Risk Analysis](regulatory/risk_management/india_risk_analysis_v2.0.md)

#### 6.3.3 Risk Control
- Implementation of measures to reduce risks to acceptable levels
- Verification of risk control measure effectiveness
- Evaluation of any new risks introduced by control measures
- Comprehensive controls for home use scenarios
- Details in [Risk Controls](regulatory/risk_management/india_risk_controls_v2.0.md)

#### 6.3.4 Overall Residual Risk Evaluation
- Evaluation of the combined effect of all residual risks
- Benefit-risk analysis to justify any remaining risks
- Comprehensive review by Clinical Advisory Board
- Special consideration for home use without professional supervision

#### 6.3.5 Risk Management Review
- Regular review of risk management activities
- Update of risk management documentation as needed
- Review of post-production information
- Continuous improvement of risk management process

### 6.4 Security and Privacy

The Security Working Group ensures that the system meets security and privacy requirements, including:

#### 6.4.1 Data Protection
- **Encryption**: End-to-end encryption of sensitive data
- **Data Minimization**: Collection of only necessary data
- **Storage Security**: Secure storage of patient data
- **Access Controls**: Role-based access to patient data
- **Data Retention**: Policies for data retention and deletion

#### 6.4.2 System Security
- **Authentication**: Multi-factor authentication for system access
- **Authorization**: Role-based permissions for system functions
- **Audit Logging**: Comprehensive logging of system activities
- **Vulnerability Management**: Regular security assessments and patching
- **Secure Development**: Security-focused development practices

#### 6.4.3 Privacy Compliance
- **Consent Management**: Procedures for obtaining and managing patient consent
- **Privacy Notices**: Clear information about data collection and use
- **Data Subject Rights**: Procedures for handling data subject requests
- **Data Protection Impact Assessment**: Assessment of privacy risks
- **Breach Notification**: Procedures for handling data breaches

#### 6.4.4 Home Use Security
- **User Authentication**: Simplified but secure authentication for home users
- **Family Access Management**: Controlled access for family caregivers
- **Offline Security**: Security measures for offline operation
- **Remote Access Security**: Secure protocols for remote monitoring and support
- **Physical Security**: Measures to prevent unauthorized physical access

## üí∞ Funding Readiness

### 7.1 Billion-Dollar Funding Preparation

The project maintains comprehensive documentation and processes to support billion-dollar funding rounds:

#### 7.1.1 Business Documentation
- **Business Plan**: Comprehensive plan with market analysis and growth strategy
- **Financial Projections**: Detailed 5-year projections with key assumptions
- **Valuation Analysis**: Professional valuation based on comparable companies and metrics
- **Market Research**: In-depth analysis of the Indian and global markets
- **Competitive Analysis**: Detailed analysis of competitors and competitive advantages

#### 7.1.2 Intellectual Property
- **Patent Strategy**: Comprehensive strategy for protecting core innovations
- **Patent Portfolio**: Documentation of existing and pending patents
- **Trade Secrets**: Identification and protection of trade secrets
- **Licensing Strategy**: Strategy for licensing technology and IP
- **Freedom to Operate**: Analysis of potential IP infringement risks

#### 7.1.3 Regulatory Readiness
- **Regulatory Roadmap**: Clear timeline for regulatory approvals
- **Pre-Submission Meetings**: Documentation of interactions with regulatory authorities
- **Submission Readiness**: Preparation of all required submission documents
- **Post-Approval Plan**: Strategy for post-approval requirements
- **International Strategy**: Plan for international regulatory approvals

#### 7.1.4 Manufacturing and Scale-up
- **Manufacturing Strategy**: Plan for scaling manufacturing
- **Supply Chain Management**: Strategy for managing the supply chain
- **Quality Agreements**: Agreements with key suppliers and manufacturers
- **Capacity Planning**: Analysis of manufacturing capacity requirements
- **Cost Reduction Roadmap**: Plan for reducing costs through scale and innovation

#### 7.1.5 Go-to-Market Strategy
- **Market Entry Strategy**: Plan for entering the Indian market
- **Pricing Strategy**: Analysis of pricing options and reimbursement
- **Distribution Strategy**: Plan for product distribution and service
- **Marketing Plan**: Strategy for product marketing and awareness
- **Sales Strategy**: Plan for direct and indirect sales channels

### 7.2 Investor Relations

The project maintains processes for effective investor relations:

#### 7.2.1 Investor Materials
- **Pitch Deck**: Professional presentation for investor meetings
- **Executive Summary**: Concise overview of the business opportunity
- **Due Diligence Data Room**: Organized repository of due diligence materials
- **Technical White Papers**: Detailed explanations of key technologies
- **Clinical Evidence Summary**: Summary of clinical validation results

#### 7.2.2 Investor Communication
- **Investor Updates**: Regular updates on project progress
- **Financial Reporting**: Transparent reporting of financial performance
- **Milestone Tracking**: Clear communication of milestone achievement
- **Risk Disclosure**: Honest disclosure of risks and challenges
- **Strategic Vision**: Communication of long-term vision and strategy

#### 7.2.3 Governance for Investors
- **Board Structure**: Professional board with independent directors
- **Advisory Boards**: Expert advisors in key areas
- **Reporting Structure**: Clear reporting lines and accountability
- **Compliance Framework**: Robust compliance with relevant regulations
- **Exit Strategy**: Clear potential paths to investor liquidity

## üè† Home Use Governance

### 8.1 Home Use Requirements

The project implements specific governance for home use applications:

#### 8.1.1 User Training
- **Training Program**: Comprehensive training for users and family members
- **Competency Verification**: Assessment of user ability to operate the device safely
- **Progressive Autonomy**: Gradual increase in user independence
- **Refresher Training**: Periodic refresher training and assessment
- **Remote Training Options**: Video and online training resources

#### 8.1.2 Home Environment Assessment
- **Environment Checklist**: Assessment of home environment suitability
- **Modification Guidance**: Recommendations for home modifications
- **Space Requirements**: Minimum space requirements for safe operation
- **Power Assessment**: Evaluation of power supply reliability
- **Connectivity Assessment**: Evaluation of internet connectivity

#### 8.1.3 Remote Monitoring
- **Usage Monitoring**: Tracking of device usage patterns
- **Performance Monitoring**: Monitoring of device performance metrics
- **Safety Monitoring**: Detection of potential safety issues
- **Anomaly Detection**: Identification of unusual patterns
- **Alert System**: Notification of critical issues to healthcare providers

#### 8.1.4 Support System
- **Technical Support**: 24/7 helpline for technical issues
- **Clinical Support**: Access to clinical expertise when needed
- **Maintenance Schedule**: Regular maintenance and inspection
- **Troubleshooting Guides**: User-friendly troubleshooting resources
- **Emergency Procedures**: Clear procedures for emergency situations

### 8.2 India-Specific Considerations

The project addresses specific considerations for the Indian market:

#### 8.2.1 Infrastructure Adaptation
- **Power Resilience**: Solutions for power outages and fluctuations
- **Connectivity Solutions**: Options for areas with limited internet access
- **Environmental Protection**: Adaptations for climate and environmental conditions
- **Space Optimization**: Design considerations for typical Indian homes
- **Maintenance Accessibility**: Access to maintenance services across India

#### 8.2.2 Cultural Adaptation
- **Language Support**: Interface and documentation in major Indian languages
- **Family Involvement**: Recognition of family role in patient care
- **Cultural Sensitivity**: Respect for cultural practices and beliefs
- **Accessibility**: Design for users with varied literacy levels
- **Community Support**: Engagement with local community resources

#### 8.2.3 Economic Considerations
- **Cost Optimization**: Design choices to minimize cost without compromising safety
- **Payment Options**: Flexible payment and financing options
- **Insurance Navigation**: Support for insurance coverage and reimbursement
- **Service Network**: Affordable maintenance and service options
- **Upgrade Path**: Cost-effective upgrade options as technology advances

## üå± Community and Contribution

### 9.1 Code of Conduct

All participants in the Chimera project are expected to adhere to the [Code of Conduct](CODE_OF_CONDUCT.md), which promotes a respectful and inclusive community.

### 9.2 Contributing Guidelines

The [Contributing Guidelines](CONTRIBUTING.md) provide detailed information on how to contribute to the project, including:

- Setting up the development environment
- Coding standards and best practices
- Testing requirements
- Pull request process
- Documentation requirements
- Regulatory considerations for contributions

### 9.3 Community Engagement

The Chimera project engages with the community through various channels:

- **GitHub Issues and Pull Requests**: Primary means of contribution and feedback
- **Discussion Forums**: For general discussions and questions
- **Regular Meetings**: Open meetings for Working Groups and TSC
- **Workshops and Webinars**: Educational events for users and contributors
- **Conferences**: Presentations at relevant conferences and events
- **User Groups**: Local user groups for patients and caregivers
- **Healthcare Provider Network**: Engagement with healthcare professionals
- **Academic Partnerships**: Collaboration with research institutions

### 9.4 Recognition and Advancement

Contributors are recognized for their contributions and may advance to more formal roles:

- **Regular Contributor**: Consistent contributions over time
- **Working Group Member**: Active participation in a specific area
- **Working Group Lead**: Leadership of a Working Group
- **TSC Member**: Significant technical contributions and leadership
- **Advisory Board Member**: Recognized expertise in relevant domain

Advancement is based on merit, demonstrated expertise, and commitment to the project's principles. The process for advancement is transparent and documented in the [Contribution Ladder](docs/contribution_ladder.md).

## üìà Implementation and Monitoring

### 10.1 Implementation Plan

The governance framework is implemented through the following steps:

1. **Documentation**: Creation and approval of governance documents
2. **Training**: Training of all team members on governance processes
3. **Tool Configuration**: Setup of tools to support governance processes
4. **Pilot Implementation**: Initial implementation with monitoring and feedback
5. **Full Implementation**: Complete implementation across all project areas
6. **Continuous Improvement**: Ongoing refinement based on experience

### 10.2 Governance Metrics

The effectiveness of the governance framework is monitored through key metrics:

- **Process Adherence**: Percentage of activities following defined processes
- **Document Compliance**: Percentage of documents meeting quality standards
- **Issue Resolution Time**: Time to resolve governance-related issues
- **Stakeholder Satisfaction**: Feedback from stakeholders on governance effectiveness
- **Regulatory Compliance**: Results of regulatory compliance assessments
- **Investor Readiness**: Assessment of documentation against investor requirements

### 10.3 Governance Review

The governance framework is reviewed regularly:

- **Quarterly Review**: Review by Core Team and Working Group leads
- **Annual Audit**: Comprehensive audit by Quality Management Working Group
- **External Assessment**: Periodic assessment by external experts
- **Regulatory Updates**: Review when regulatory requirements change
- **Investor Feedback**: Incorporation of feedback from investor due diligence

### 10.4 Continuous Improvement

The governance framework is continuously improved through:

- **Lessons Learned**: Documentation and application of lessons learned
- **Best Practice Adoption**: Incorporation of industry best practices
- **Stakeholder Feedback**: Consideration of feedback from all stakeholders
- **Efficiency Analysis**: Identification of opportunities to improve efficiency
- **Benchmark Comparison**: Comparison with governance in similar organizations

## üìù Conclusion

This Governance Framework provides a comprehensive structure for the development, management, and evolution of the Chimera brain-controlled exoskeleton platform. By adhering to this framework, the project ensures quality, regulatory compliance, and stakeholder satisfaction while maintaining the flexibility to innovate and adapt to changing requirements.

The framework is designed to support the project's goals of developing a safe, effective, and accessible solution for individuals with mobility impairments, with specific focus on home use applications in the Indian market. It also establishes the foundation for billion-dollar funding readiness by demonstrating professional management, regulatory sophistication, and strategic vision.

## üìã Approval and Review

This Governance document has been reviewed and approved by:

| Name | Role | Signature | Date |
|------|------|-----------|------|
| [Name] | CEO | [Signature] | April 20, 2025 |
| [Name] | CTO | [Signature] | April 20, 2025 |
| [Name] | Clinical Director | [Signature] | April 20, 2025 |
| [Name] | Quality Director | [Signature] | April 20, 2025 |
| [Name] | Regulatory Affairs Director | [Signature] | April 20, 2025 |
| [Name] | CFO | [Signature] | April 20, 2025 |
| [Name] | COO | [Signature] | April 20, 2025 |

---

<div align="center">
<p><strong>Chimera Neurotechnology Pvt. Ltd.</strong><br>
Bengaluru, Karnataka, India<br>
Document No: GOV-FRAMEWORK-002 | Version: 2.0.0 | April 2025</p>

[![ISO 13485](https://img.shields.io/badge/ISO%2013485-Compliant-blue?style=flat-square)](https://www.iso.org/standard/59752.html)
[![CDSCO](https://img.shields.io/badge/CDSCO-MDR%202017-orange?style=flat-square)](https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/)
[![Home Use](https://img.shields.io/badge/Home%20Use-Certified-blue?style=flat-square)](https://www.iso.org/standard/60601-1-11.html)
</div>
